Cover Image
市場調查報告書

高眼壓症:開發中產品分析

Ocular Hypertension - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 219790
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
高眼壓症:開發中產品分析 Ocular Hypertension - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 118 Pages
簡介

高眼壓症是眼睛內壓力(一般稱作眼壓)超過一般正常範圍(大約定義在21mm Hg以上)時所引起。症狀有眼睛疼痛或充血,虹視症,及頭痛等。原因包含了人種,家族病史,近視及糖尿病。治療有手術及使用特定的藥物。

本報告提供全球治療高眼壓症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

高眼壓症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

高眼壓症:企業開發中的的治療藥

高眼壓症:大學/機關研究中的治療藥

高眼壓症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

高眼壓症:企業開發中的產品

高眼壓症:大學/機關研究中的產品

高眼壓症的治療藥開發作的企業

  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Amakem NV
  • Bausch & Lomb Incorporated
  • Can-Fite BioPharma Ltd.
  • D. Western Therapeutics Institute, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inotek Pharmaceuticals Corporation
  • Ironwood Pharmaceuticals, Inc.
  • 興和
  • Laboratoires Thea S.A.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • NicOx S.A.
  • Ocular Therapeutix, Inc.
  • 大塚集團
  • pSivida Corp.
  • Sanofi
  • 參天製藥
  • 千壽製藥
  • Sylentis S.A.U.
  • ViSci Ltd.

高眼壓症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高眼壓症:暫停中的計劃

高眼壓症:開發中止的產品

高眼壓症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9107IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 15, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Ocular Hypertension - Overview
  • Ocular Hypertension - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Ocular Hypertension - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Ocular Hypertension - Companies Involved in Therapeutics Development
  • Aerie Pharmaceuticals Inc
  • Allergan Plc
  • Bausch & Lomb Inc
  • Can-Fite BioPharma Ltd
  • D. Western Therapeutics Institute Inc
  • F. Hoffmann-La Roche Ltd
  • Inotek Pharmaceuticals Corp
  • Ironwood Pharmaceuticals Inc
  • Laboratoires Thea SA
  • Laboratorios Sophia SA de CV
  • Lee's Pharmaceutical Holdings Ltd
  • Lexicon Pharmaceuticals Inc
  • Neurim Pharmaceuticals Ltd
  • NicOx SA
  • Ocular Therapeutix Inc
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Sylentis SAU
  • ViSci Ltd
  • Ocular Hypertension - Drug Profiles
  • (bimatoprost + timolol maleate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (latanoprost + netarsudil mesylate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (latanoprost + timolol maleate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (latanoprost + trabodenoson) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bamosiran - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bimatoprost - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bimatoprost SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • H-1129 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IWP-953 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • latanoprost - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • latanoprost SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • latanoprost SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • latanoprost SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • latanoprostene bunod - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • levobetaxolol hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LX-7101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MGV-354 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCX-1653 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCX-470 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCX-667 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • netarsudil mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • omidenepag isopropyl - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • piclidenoson - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • piromelatine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRO-067 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-5093151 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sepetaprost - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SNJ-1656 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • trabodenoson - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • travoprost SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • travoprost XR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Ocular Hypertension - Dormant Projects
  • Ocular Hypertension - Discontinued Products
  • Ocular Hypertension - Product Development Milestones
  • Featured News & Press Releases
  • Feb 27, 2017: Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod
  • Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
  • Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
  • Jan 03, 2017: Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma
  • Dec 23, 2016: Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for Rhopressa (netarsudil ophthalmic solution) 0.02%
  • Dec 07, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  • Oct 27, 2016: Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%
  • Oct 04, 2016: Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension
  • Sep 06, 2016: Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02%
  • Jul 22, 2016: Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
  • Jul 06, 2016: Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
  • Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%
  • May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  • Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension
  • Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Ocular Hypertension, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2017
  • Ocular Hypertension - Pipeline by Allergan Plc, H1 2017
  • Ocular Hypertension - Pipeline by Bausch & Lomb Inc, H1 2017
  • Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2017
  • Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corp, H1 2017
  • Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Ocular Hypertension - Pipeline by Laboratoires Thea SA, H1 2017
  • Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H1 2017
  • Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
  • Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
  • Ocular Hypertension - Pipeline by NicOx SA, H1 2017
  • Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H1 2017
  • Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
  • Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
  • Ocular Hypertension - Pipeline by Sylentis SAU, H1 2017
  • Ocular Hypertension - Pipeline by ViSci Ltd, H1 2017
  • Ocular Hypertension - Dormant Projects, H1 2017
  • Ocular Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Ocular Hypertension - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Ocular Hypertension, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top